Daré Bioscience Secures $15 Million Stock Purchase Agreement
Daré Bioscience, Inc. (NASDAQ: DARE) is paving the way for innovative advancements in women’s health with a strategic move to enter a $15 million common stock purchase agreement with Lincoln Park Capital Fund, LLC. This agreement reflects Daré's dedication to enhancing healthcare outcomes and expanding treatment options for women.
Details of the Agreement
The terms of the stock purchase agreement grant Daré the flexibility to sell up to $15 million worth of its common stock to Lincoln Park over a span of 24 months. Crucially, the opportunity to sell these shares is contingent on the successful filing of a registration statement with the Securities and Exchange Commission (SEC). The management at Daré will exercise full control over the timing and quantity of shares sold, thereby ensuring that market conditions align with their strategic objectives.
Understanding the Financial Implications
Lincoln Park is obliged to purchase common stock sold under this agreement at prices determined by market conditions at the time of sale. This arrangement provides Daré with vital financial resources to drive forward its clinical programs and investigational products targeted at women's health issues. Importantly, there is no cap on the price per share that Lincoln Park might pay, ensuring the company's financial flexibility in this regard.
Harnessing the Proceeds for Product Development
In recent communications, Sabrina Martucci Johnson, President, and CEO of Daré Bioscience, expressed her enthusiasm regarding the partnership with Lincoln Park. The previous agreement with LPC in 2020 played a significant role in funding their successful Phase 3 study of XACIATO (clindamycin phosphate) vaginal gel 2%, which ultimately secured FDA approval. With the new infusion of capital, Daré aims to advance the development of critical treatments such as Sildenafil Cream, 3.6%, which shows promise in treating female sexual arousal disorder. This approach not only aligns with their overall strategy but also aims to enhance healthcare choices for women.
Regulatory Considerations
As part of the ongoing compliance framework, the securities offered to Lincoln Park under this agreement have not been registered under the Securities Act of 1933. Therefore, they cannot be offered or sold without appropriate registration or exemption from registration requirements. This aspect underscores Daré's commitment to adhering to regulatory standards while fostering innovative solutions in women's health.
About Daré Bioscience
Daré Bioscience is a frontrunner in the biopharmaceutical sector, focusing on developing pioneering products for women's health. The company's mission emphasizes the creation of a diverse array of therapeutic options that enhance women's health and overall well-being. Through their innovative portfolio, they aim to tackle various aspects of women's health, including reproductive health, menopause, and sexual health.
The launch of XACIATO™ is a cornerstone achievement for Daré Bioscience; this FDA-approved product caters to the treatment of bacterial vaginosis in women, and its distribution began following a licensing agreement with Organon. Daré's pipeline further includes Ovaprene®, a novel contraceptive option in development and Sildenafil Cream, 3.6%, which could potentially be a groundbreaking treatment for female sexual arousal disorder.
Acknowledgment and Recognition
Daré Bioscience continues to gain recognition within the biopharmaceutical community. They have not only made notable contributions to women's health but have also been recognized by industry publications for their leadership and innovation. In recent accolades, their CEO was honored as one of the most influential figures in the biopharmaceutical field, underpinning the company’s mission and commitment to positively impacting women's health.
In summary, the collaboration with Lincoln Park Capital represents a significant step for Daré Bioscience, as they harness these funds to propel their future developments in women's health. The responsible management of these resources will undoubtedly play a key role in advancing their clinical programs and bringing much-needed innovations to market.
Frequently Asked Questions
What is the significance of the $15 million agreement for Daré Bioscience?
The agreement allows Daré to access critical funds over the next two years, facilitating the advancement of their women's health initiatives and clinical studies.
How will Daré utilize the funds from the stock purchase agreement?
The funds are expected to support the development of ongoing projects such as Sildenafil Cream, 3.6%, which targets female sexual arousal disorder among other product candidates.
Who is Lincoln Park Capital Fund, LLC?
Lincoln Park Capital is an institutional investor based in Chicago, specializing in long-term equity investments across various sectors, including healthcare.
What products does Daré Bioscience have in its pipeline?
Daré’s pipeline includes XACIATO, Ovaprene, and Sildenafil Cream, addressing various aspects of women's health from contraception to treatment of sexual disorders.
How does Daré ensure compliance with SEC regulations?
Daré adheres to strict regulatory guidelines, including the filing of necessary documents and ensuring that securities offered are in line with compliance requirements.
